v3.26.1
2025 Capital Realignment Transactions (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 4 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Mar. 31, 2026
Jun. 30, 2026
Jan. 31, 2022
Common Stock          
Subsidiary or Equity Method Investee [Line Items]          
Exercises of pre-funded warrants (in shares)   4,106,056      
Pre-Funded Warrants          
Subsidiary or Equity Method Investee [Line Items]          
Exercise price (in dollars per share)       $ 0.0001  
Pre-Funded Warrants | Common Stock          
Subsidiary or Equity Method Investee [Line Items]          
Exercises of pre-funded warrants (in shares)     8,400,000    
Registered Offering          
Subsidiary or Equity Method Investee [Line Items]          
Stock sold (in shares) 2,200,000        
Stock sold, aggregate consideration $ 45.6        
Registered Offering | Pre-Funded Warrants          
Subsidiary or Equity Method Investee [Line Items]          
Stock sold (in shares) 8,400,000        
2027 Notes          
Subsidiary or Equity Method Investee [Line Items]          
Interest rate         2.50%
Debt instrument, repurchased amount $ 354.6        
Debt instrument, face amount         $ 425.0
2027 Notes | Pre-Funded Warrants          
Subsidiary or Equity Method Investee [Line Items]          
Exercise price (in dollars per share)       $ 0.0001  
2027 Notes | Convertible Debt          
Subsidiary or Equity Method Investee [Line Items]          
Interest rate 2.50%        
Debt instrument, repurchased amount $ 354.6        
2028 Notes | Purchase Warrant          
Subsidiary or Equity Method Investee [Line Items]          
Number of shares called by warrants (in shares) 31,700,000        
Exercise price (in dollars per share) $ 6.696        
2028 Notes | 2028 First Lien Notes          
Subsidiary or Equity Method Investee [Line Items]          
Interest rate 9.80%        
Debt instrument, face amount $ 212.5